Linzess denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for linzess are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Linzess Under Step Therapy

Aetna's step-therapy (also called "fail-first") policy for Linzess requires that a patient first try and fail one or more lower-cost or preferred medications before Aetna will cover Linzess for IBS-C or chronic idiopathic constipation. The specific drugs and sequence required are listed in Aetna's current Clinical Policy Bulletin for Linzess — request that document. A step-therapy denial means Aetna's records do not show evidence of an adequate trial of the required prior steps.

## Why This Denial Is Appealable

Step-therapy denials are among the most successfully appealed denial types when the documentation is thorough. Many states have enacted step-therapy override laws that require insurers to grant an exception when a required step drug is contraindicated, has already failed, or would cause clinically significant harm. Even in states without specific override laws, ACA §2719 external review rights and ERISA §503 full-and-fair review apply. File an internal appeal within the deadline on the denial notice; request external review within approximately four months of exhausting internal remedies. Expedited review is available for urgent situations.

## The Concrete Appeal Process

1. Obtain Aetna's step-therapy criteria: request the Clinical Policy Bulletin listing every required prior step drug and the definition of "adequate trial" and "failure." 2. Document prior step completion or exception basis: for each required step, either document that the patient tried and failed it, or document the clinical reason it cannot be tried. 3. File the internal step-therapy override appeal with complete documentation. 4. Cite applicable state step-therapy law if your state has one — your state insurance commissioner's website lists current consumer protections. 5. Request external IRO review if internal appeal is denied.

## Documentation to Gather

• Prior-medication history: for every drug in Aetna's required step sequence, provide the drug name, start date, stop date, dose used, documented clinical response, and reason for discontinuation. Chart notes and pharmacy records both help.
• Prescriber's step-therapy override letter: a letter addressing each required step — confirming trial-and-failure, contraindication, or another recognized exception ground — with specific reference to chart findings.
• Diagnosis and severity documentation: chart notes confirming IBS-C or CIC diagnosis, duration, and functional severity.
• Applicable guideline reference: the prescriber may reference the relevant gastroenterology guideline organization (such as the American College of Gastroenterology) to support why Linzess is appropriate for this patient's clinical profile.
• State step-therapy override statute (if applicable): a citation to your state's law and the specific exception ground being invoked.

## Criteria-Mapping Structure

Map Aetna's required steps one-for-one against the chart record. Create a table with one row per required step drug. For each row: drug name, required trial duration per Aetna's policy, actual trial dates from chart, documented outcome, and the chart note page that proves it. If a step cannot be completed due to a clinical reason, state that reason and attach the supporting chart note. This format is the clearest possible response to a step-therapy denial and is the format most likely to succeed at external review.